215 related articles for article (PubMed ID: 38049318)
41. [Analysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL)].
Yang H; Niu JH; Zhu CY; Zhang Q; Zhu HY; Yao ZL; Zhou MH; Wang QS; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):957-64. PubMed ID: 25130810
[TBL] [Abstract][Full Text] [Related]
42. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
43. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia.
Zompi S; Viguié F
Leuk Lymphoma; 2002 Feb; 43(2):275-80. PubMed ID: 11999558
[TBL] [Abstract][Full Text] [Related]
44. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
45. Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia.
Ojeda-Uribe M; Schneider A; Luquet I; Berceanu A; Cornillet-Lefebvre P; Jeandidier E; Lioure B; Ades L; Mauvieux L; Himberlin C
Eur J Haematol; 2012 Sep; 89(3):267-72. PubMed ID: 22591288
[TBL] [Abstract][Full Text] [Related]
46. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
[TBL] [Abstract][Full Text] [Related]
47. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
[TBL] [Abstract][Full Text] [Related]
48. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
49. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
50. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
[TBL] [Abstract][Full Text] [Related]
51. Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
Lee JW; Oh H; You JY; Lee ES; Lee JH; Song SE; Lee NK; Jung SP; An JS; Cho KR; Kim CY; Park KH
Eur J Cancer; 2023 Sep; 191():112952. PubMed ID: 37473463
[TBL] [Abstract][Full Text] [Related]
52. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; Megías-Vericat JE; Serrano J; Martínez-Sánchez P; Rodríguez-Arbolí E; Gil C; Aguiar E; Bergua J; López-Lorenzo JL; Bernal T; Espadana A; Colorado M; Rodríguez-Medina C; López-Pavía M; Tormo M; Algarra L; Amigo ML; Sayas MJ; Labrador J; Rodríguez-Gutiérrez JI; Benavente C; Costilla-Barriga L; García-Boyero R; Lavilla-Rubira E; Vives S; Herrera P; García-Belmonte D; Herráez MM; Vasconcelos Esteves G; Gómez-Roncero MI; Cabello A; Bautista G; Balerdi A; Mariz J; Boluda B; Sanz MÁ; Montesinos P
Blood Adv; 2022 Feb; 6(4):1278-1295. PubMed ID: 34794172
[TBL] [Abstract][Full Text] [Related]
53. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
54. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
55. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
56. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Schuler E; Zadrozny N; Blum S; Schroeder T; Strupp C; Hildebrandt B; Kündgen A; Gattermann N; Aul C; Kondakci M; Kobbe G; Haas R; Germing U
Ann Hematol; 2018 Dec; 97(12):2325-2332. PubMed ID: 30078145
[TBL] [Abstract][Full Text] [Related]
57. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
58. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
59. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
60. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
